Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLCPlasma MET test showed high concordance with tissue IHC/FISH in EGFR-mutated NSCLC following progression on first-line targeted therapy (AUC=0.97)Baseline and longitudinal profiling in METex14 skipping NSCLC identified biology associated with therapeutic sensitivity and resistance, including MET pathway activity, neuroendocrine lineage plasticity, and exp